Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fundraising
Biotech
Eye disease biotech launches with $100M, Roche rival in clinic
Ollin Biosciences has already enrolled 150 patients in a phase 1b trial pitting its bispecific antibody against Roche's blockbuster eye med Vabysmo.
Darren Incorvaia
Sep 17, 2025 6:30am
Fierce Biotech Fundraising Tracker: Ollin, Dualitas & more
Sep 17, 2025 6:30am
Flagship's Lila lands $235M to expand AI-powered research labs
Sep 15, 2025 2:25pm
Pivotal, Wellcome Leap invest $100M in women's health research
Sep 10, 2025 10:35am
Odyssey saga continues with $213M series D
Sep 10, 2025 8:00am
Treeline reaps $200M series A extension, picks first 3 programs
Sep 3, 2025 11:15am
